Portfolio
64x Bio
“64x Bio, a spinout of Harvard’s Wyss Institute and George Church's lab, is transforming the future of cell and gene therapy manufacturing. Using a novel high throughput discovery and screening platform and an integrated computational design loop, they are developing new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors. These fundamental advances enable pharmaceutical and biotechnology companies to bring more lifesaving cell and gene therapies to patients by reducing the cost and complexity of manufacturing, a critical bottleneck in this multibillion dollar market.”
Founders: Lex Rovner, Jeff Way, David Thompson, Pamela Silver, & George Church
Location: San Francisco, CA
Category: Life Sciences / Services / CGT
Company Stage: Series A
Co-Investors: Lifeforce Capital, Northpond Ventures, First Round, Future Ventures, amongst others
